Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
Fiche publication
Date publication
décembre 2018
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BITTARD Hugues, Dr LASCOMBE Isabelle, Mr MONNIEN Franck, Dr FAUCONNET Sylvie, Pr KLEINCLAUSS François
Tous les auteurs :
Mathis C, Lascombe I, Monnien F, Bittard H, Kleinclauss F, Bedgedjian I, Fauconnet S, Valmary-Degano S
Lien Pubmed
Résumé
Non-muscle invasive bladder cancers (NMIBC: pTa, pT1) are characterised by a high risk of recurrence and/or progression. Identification of prognostic markers is needed to improve both diagnosis and management of the disease. The aim of this study was to analyse the expression of A-FABP (adipocyte-fatty acid binding protein) and to evaluate its prognostic value in bladder cancer with a long term clinical follow-up.
Mots clés
A-FABP, Adipocyte-fatty acid binding protein, Bladder cancer, FABP4, Prognostic marker
Référence
BMC Cancer. 2018 Dec 10;18(1):1239